BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy

Reuters12-22 21:22

Dec 22 (Reuters) - Scienture Holdings Inc SCNX.O:

SCIENTURE PROVIDES UPDATE ON THE COMMERCIAL LAUNCH OF REZENOPY®, THE HIGHEST STRENGTH NALOXONE HCL LIFE-SAVING OPIOID OVERDOSE EMERGENCY TREATMENT APPROVED BY THE FDA
SCIENTURE HOLDINGS INC - REZENOPY EXPECTED COMMERCIALLY AVAILABLE EARLY Q2 2026

Source text: ID:nGNX8j4qbF

Further company coverage: SCNX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593348026?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593348026","market":"us","top_or_hot":-1,"title":"BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy</title></head><body><p><span>Dec 22 (Reuters)</span><span> - </span>Scienture Holdings Inc <span>SCNX.O</span>:</p><ul><li><p>SCIENTURE PROVIDES UPDATE ON THE COMMERCIAL LAUNCH OF REZENOPY®, THE HIGHEST STRENGTH NALOXONE HCL LIFE-SAVING OPIOID OVERDOSE EMERGENCY TREATMENT APPROVED BY THE FDA</p></li><li><p>SCIENTURE HOLDINGS INC - REZENOPY EXPECTED COMMERCIALLY AVAILABLE EARLY <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p>Source text: <span>ID:nGNX8j4qbF</span></p><p>Further company coverage: <span>SCNX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-22 21:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy</title></head><body><p><span>Dec 22 (Reuters)</span><span> - </span>Scienture Holdings Inc <span>SCNX.O</span>:</p><ul><li><p>SCIENTURE PROVIDES UPDATE ON THE COMMERCIAL LAUNCH OF REZENOPY®, THE HIGHEST STRENGTH NALOXONE HCL LIFE-SAVING OPIOID OVERDOSE EMERGENCY TREATMENT APPROVED BY THE FDA</p></li><li><p>SCIENTURE HOLDINGS INC - REZENOPY EXPECTED COMMERCIALLY AVAILABLE EARLY <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p>Source text: <span>ID:nGNX8j4qbF</span></p><p>Further company coverage: <span>SCNX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SCNX","symbol_name":"Scienture Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA1DGPVY:1","article_id":"2593348026","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593348026","pubTimestamp":1766409727,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Scienture Provides Update On The Commercial Launch Of RezenopyDec 22 (Reuters) - Scienture Holdings Inc SCNX.O:SCIENTURE PROVIDES UPDATE ON THE COMMERCIAL LAUNCH OF REZENOPY, THE HIGHEST STRENGT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SCNX":"Scienture Holdings, Inc.","BK4167":"医疗保健技术"},"translate_title":"BRIEF-Scienture提供Rezenopy商业发布的最新信息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCNX":0.9},"content_text":"BRIEF-Scienture Provides Update On The Commercial Launch Of RezenopyDec 22 (Reuters) - Scienture Holdings Inc SCNX.O:SCIENTURE PROVIDES UPDATE ON THE COMMERCIAL LAUNCH OF REZENOPY®, THE HIGHEST STRENGTH NALOXONE HCL LIFE-SAVING OPIOID OVERDOSE EMERGENCY TREATMENT APPROVED BY THE FDASCIENTURE HOLDINGS INC - REZENOPY EXPECTED COMMERCIALLY AVAILABLE EARLY Q2 2026Source text: ID:nGNX8j4qbFFurther company coverage: SCNX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593348026","isCrawlerRequest":true}